Intercure Ltd. Stock Price, News & Analysis

InterCure (NASDAQ: INCR) reported first half 2025 results: NIS 130 million revenue, NIS 12.6 million Adjusted EBITDA (10% margin) and NIS 12 million positive operating cash flow. Revenue rose 15% versus H2 2024 and 3% year‑over‑year. Net loss was NIS 1.8 million. Cash on hand improved to NIS 54 million from NIS 21 million a year earlier. The company resumed production at its Nir Oz facility, launched 40+ SKUs, received NIS 81 million in compensation advances against submitted damages of NIS 251 million, and signed a share purchase agreement to acquire ISHI to expand U.S. genetics and supply.

InterCure (NASDAQ: INCR) has announced the strategic acquisition of Botanico Ltd. (ISHI), a premium cannabis technology and brand company. The transaction will be executed in two phases, with InterCure acquiring 100% of ISHI for 4,924,261 ordinary shares, representing approximately 10% of InterCure's fully diluted shares.

The acquisition provides InterCure immediate access to advanced cultivation technologies, exclusive partnerships with leading U.S. cannabis operators including The Flowery, and premium American genetics. The deal comes amid potential cannabis rescheduling from Schedule I to Schedule III by the Trump administration, positioning InterCure to capitalize on evolving U.S. market opportunities.

The transaction is expected to close in Q1 2026, subject to regulatory approvals. ISHI's leadership team, including CEO Omer Layani and COO Dor Hershkovitz, will join InterCure's management. The acquisition is projected to be accretive within the first year.

InterCure (INCR) reported its FY2024 results and Q1 2025 update, showing resilience despite significant challenges. The company achieved revenues of NIS 239 million and Adjusted EBITDA of NIS 24 million (10% of revenues) in 2024. Operations were impacted by the October 7, 2023 terrorist attack on their southern Nir Oz facility, for which InterCure received NIS 82 million in compensation from Israeli authorities. Looking ahead, Q1 2025 shows promise with expected sequential growth of over 25% to NIS 70+ million. The company secured NIS 66 million in funding and is expanding its European presence through a strategic partnership with Cookies™ in Germany and the UK. InterCure maintains a strong cash position of NIS 80 million and operates 25 medical cannabis pharmacies.

InterCure (NASDAQ: INCR) announced leadership changes and financing updates. Ehud Barak will step down as Chairman effective February 13, 2025, to be succeeded by current CEO Alexander Rabinovich, who has led the company's growth over the past five years.

The company successfully completed a financing round of NIS 66 million (approximately $18.2 million) to support the recovery of the Nir Oz Facility, with potential additional proceeds of up to NIS 107 million ($29.8 million) through warrant exercises. The funding includes investments from key shareholders and a loan agreement with a leading Israeli bank.

InterCure is executing its war recovery plan following the October 7, 2023 events that impacted its Nir Oz facility. The company expects additional compensation from Israeli authorities for war-related damages and is focused on rebuilding its pharmaceutical cannabis portfolio while expanding operations in Germany, the UK, and Australia.

InterCure (NASDAQ: INCR) has secured funding commitments of NIS 66 million (USD 18.2M), potentially increasing to NIS 107 million (USD 29.8M), to support the recovery of its Nir Oz facility damaged during the war. The funding includes a private placement with key investors, including CEO Alexander Rabinovich and shareholders Yaron Yakobi and Tzahi Hagag, who will each hold over 5% stake. The placement involves issuing 7,349,896 ordinary shares at NIS 4.83 per share and warrants for additional shares at NIS 5.70.

Additionally, the company secured a NIS 30 million (USD 8.3M) loan from a leading Israeli bank. InterCure expects to receive substantial compensation from Israeli authorities for war-related damages and plans to expand its facility post-war in collaboration with the Tkumah administration.

InterCure (NASDAQ: INCR) reported its financial results for the first half of 2024, with revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million (17% of revenues). The company achieved its 16th and 17th consecutive quarters of profitability despite challenges from the October 7, 2023 terrorist attack and the war in Gaza. InterCure is receiving compensation from Israeli authorities for damages to its Southern Facility.

The company announced an expansion of its partnership with Cookies™ to Germany, expecting to launch products there in Q4 2024. InterCure anticipates double-digit growth in the second half of 2024 due to expected launches in German and UK markets. The company continues to expand its medical cannabis pharmacy chain, now with 24 active locations.

InterCure (NASDAQ: INCR) has expanded its strategic partnership with Cookies, a globally recognized cannabis brand, to Germany. The agreement allows InterCure to cultivate, manufacture, import, and distribute Cookies' branded products in 8 licensed pharmacies across Germany through Cookies Corners. This expansion follows their existing partnerships in the UK, Austria, and Israel.

InterCure will produce Cookies' products at its EU-GMP manufacturing sites, including future offerings like live resin, live rosin, and vapes. The partnership aims to capitalize on Germany's growing medical cannabis market, which saw a 400% increase in prescriptions from March to June 2024 following the passage of the 'CanG' Cannabis Act.

This collaboration combines Cookies' diverse portfolio of over 70 cannabis cultivars and 2,000 products with InterCure's established presence as a leading vertically integrated medical cannabis company outside North America.

InterCure (NASDAQ: INCR, TASE: INCR), also known as Canndoc, announced its participation in the Canaccord Genuity 8th Annual Global Cannabis Conference. Scheduled for May 23, 2024, at the Westin NY Grand Central Hotel in New York City, the event will feature senior management teams from leading cannabis companies. InterCure's CEO, Alex Rabinovitch, will take part in panel discussions, fireside chats, and one-on-one meetings. The conference aims to foster engagement and share insights among industry leaders.

InterCure announced its FY2023 results, with revenues of NIS 356 million and adjusted EBITDA of NIS 61 million. The company's cash on hand is NIS 111 million. Despite challenges from a terrorist attack and war in Gaza, InterCure remains profitable and expects growth in 2024. The company plans to launch products in Germany and closely monitors U.S. cannabis rescheduling.